A Phase 2, Multi-Center, Open Label Induction Trial with Extension Period to Assess Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients with Moderately to Severly Active Chron's Disease Recieving Oral RPC1063 as Induction The